Significant progress has been made in the understanding of lung cancer biology, due in
large part to advancement in the understanding of tumor biology and pathogenesis …

The identification of oncogenic driver alterations that underlie sensitivity to small inhibitors
has led to growing interest in identifying additional targetable oncogenes in nonsmall cell …

Many studies have confirmed that CYFRA21-1 DNA is a sensitive and specific marker for
non-small cell lung cancer (NSCLC). Hence, there is an urgent need to explore new …

Lung cancer has the highest mortality rate of all malignant tumours. The current effects of
cancer treatment, as well as its diagnostics, are unsatisfactory. Therefore it is very important …

Introduction Pulmonary mucoepidermoid carcinoma (PMEC) is an uncommon neoplasm of
the lung and the main salivary gland-type lung carcinoma. The aims of this study were to …

Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and
squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is …

Background EGFR, KRAS, and ALK alterations are major genetic changes found in non-
small cell lung cancers (NSCLCs). Testing advanced lung adenocarcinoma tumors for these …

Thyroid carcinoma is the most common endocrine malignant tumor and accounts for 1% of
all new malignant diseases. Among all types and subtypes of thyroid cancers that have been …

The anaplastic lymphoma tyrosine kinase (ALK) gene was first described as a driver
mutation in anaplastic non-Hodgkin's lymphoma. Dysregulated ALK expression is now an …

Background Based on the excellent results of the clinical trials with ALK-inhibitors, the
importance of accurately identifying ALK positive lung cancer has never been greater …